Evotec and Roche to jointly develop biomarkers in oncology

Friday, 24. June 2011 07:06
Evotec AG /
Evotec and Roche to jointly develop biomarkers in oncology
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

·          An alliance for personalized healthcare in cancer Research and
Development

Hamburg, Germany and Basel, Switzerland - 24 June 2011: Evotec AG (FSE: EVT,
TecDAX) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a collaboration
in novel protein-activity based biomarkers for Roche's oncology drugs under
development. Evotec AG will employ its PhosphoScout® platform to discover
protein-phosphorylation's that predict favorable dosage and efficacy of targeted
cancer drugs in patients. Roche will be responsible for conducting clinical
trials as well as assessing the development of companion diagnostics for patient
stratification.
"We are very pleased to collaborate with Evotec AG and benefit from the
PhosphoScout® technology to identify appropriate pharmacodynamics and patient
stratification biomarkers," said Mike Burgess, Global Head of Oncology, Roche
Pharma Research and Exploratory Development. "These biomarkers are core to the
development of targeted therapeutics for cancer therapy."
"Biomarker-based personalized healthcare has led to a paradigm shift in cancer
therapy," said Dr. Werner Lanthaler, Chief Executive Officer of Evotec AG. "We
are proud to partner Evotec's novel biomarker concept with Roche, the world
leading personalized healthcare company, and its Pharma Research and Development
Organization."
Under the initial three-year term Evotec and Roche will conduct multiple
biomarker programs for therapeutic antibodies or small molecule inhibitors.
Evotec will receive undisclosed up-front and success-based payments for each
program.
About the PhosphoScout® platform
Evotec's PhosphoScout® platform employs high-end mass spectrometry to identify
and quantify thousands of cellular phosphorylation events on a global scale.
Unlike immunoassays, PhosphoScout® allows truly unbiased systems-wide profiling
of signalling pathways. Monitoring changes in the cellular phosphoproteome in
response to drug treatment not only supports mechanistic understanding of
targeted drugs but also enables the discovery of predictive biomarkers.

Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone:
+49.(0)40.56081-242,werner.lanthaler@evotec.com

Contact Roche Group Media Relations

Phone: +41 -61 688 8888 /basel.mediaoffice@roche.com
- Alexander Klauser (Head)
- Silvia Dobry
- Daniel Grotzky
- Claudia Schmitt
Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.





--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


PDF of PressRelease:
http://hugin.info/131215/R/1525886/461681.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1525886]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.